Press Releases

Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious

WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.

-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- -GARNET phase 2 trial of MORF-057 in Crohn’s disease (CD) expected to begin enrolling in the first half of 2024-

-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic